Researchers at the Jules Bordet Institute - Université libre de Bruxelles, VIB and KU Leuven published this 21 of April an important study offering a better understanding of the progression of breast cancer. The conclusions could have an impact on care for patients suffering from a metastatic breast cancer. This is one of the first studies based on the analysis of multiple metastases obtained at the time of patient autopsies.
24 April, 2017
Sygnature Discovery has today been recognised with one of the UK’s most prestigious business awards – the Queen’s Award for Enterprise, International Trade.
21 April, 2017
Cancer Research UK and the Cancer Research Technology Pioneer Fund (CPF) have committed £2.5 million in collaboration with the National Cancer Institute (NCI) in the US to tackle one of the toughest challenges in cancer that has thwarted researchers for more than 30 years.
19 April, 2017
Lhasa Limited, an educational charity which creates state-of-the-art in silico prediction and database systems for use in metabolism, toxicology and related sciences has been recognised for its innovative software.
14 April, 2017
A high concentration of indolepropionic acid in the serum protects against type 2 diabetes, shows a new study from the University of Eastern Finland. Indolepropionic acid is a metabolite produced by intestinal bacteria, and its production is boosted by a fibre-rich diet. According to the researchers, the discovery provides additional insight into the role of intestinal bacteria in the interplay between diet, metabolism and health.
13 April, 2017
Collaborative team to progress novel USP30 inhibitors to develop potential therapies for Parkinson’s disease
12 April, 2017
The topic of this month’s newsletter from Drug Discovery Today is “Drug Repurposing”.
10 April, 2017
Leading genome engineering solutions provider announces expanded availability of the most efficient and cost effective synthetic RNA to the UK
06 April, 2017
New partnership set to transform the engineering of biology
05 April, 2017
Non-specific immune system becomes increasing area of focus
03 April, 2017
AstraZeneca announced (March 31st 2017) that BMJ Innovations has published the first collaborative definition of patient centricity for the pharmaceutical industry. The definition was co-developed with patients and caregivers using research led by AstraZeneca and patient community advocates to ensure a deep understanding of patient needs and values. Ten associated patient-centric principles were also identified and published in BMJ Innovations to provide the pharmaceutical industry with a consistent reference point to sustain meaningful and mutually beneficial engagement with patients. Wider testing of these outputs among US and European patient communities confirmed their validity.
02 April, 2017
Machine learning, deep learning, and pre-competitive data analysis will deliver tangible benefits to patients
01 April, 2017